CND Life Sciences Research Highlights at AAN 2025
CND Life Sciences, a pioneering medical technology firm, is making significant strides in the realm of neurodiagnostics with their forthcoming presentations at the American Academy of Neurology 2025 Annual Meeting. Their groundbreaking research focuses on cutaneous phosphorylated alpha-synuclein (P-SYN) and its implications for dementia with Lewy bodies (DLB), along with other neurodegenerative disorders.
Examining Cutaneous Phosphorylated Alpha-Synuclein
The series of studies will delve into how skin biopsies can track the changes in P-SYN levels over time in patients diagnosed with DLB. A key emphasis will be on the optimal number of biopsies necessary for accurate detection of this important biomarker. As clinicians seek more reliable diagnostic methods, the findings are expected to enhance our understanding of DLB and Alzheimer’s disease at early stages.
Key Presentation Details
Dr. Christopher Gibbons, MD, FAAN, who serves as the Chief Scientific Officer and co-founder of CND Life Sciences, leads this vital research. He will present crucial data quantifying the deposition of P-SYN alongside blood P-Tau 217 in individuals who are suspected to have DLB or Alzheimer’s disease when presenting at the annual conference. This data promises to offer new insights into the progression of these disorders.
Significance of the Syn-One Test
The Syn-One Test, developed by CND Life Sciences, is a revolutionary diagnostic tool aiming to simplify the process of diagnosing synucleinopathies. Dr. Todd Levine, MD, Chief Medical Officer at CND, reflects on the Syn-One Test, stating that it provides a minimally invasive opportunity for clinicians to achieve clarity in complex diagnostic situations. He emphasizes that accurate diagnoses are critical for patient care, making this test an essential addition to the neurologist's toolbox.
Research Findings on Biopsy Protocols
One of the striking findings from other research in this area highlights that using fewer than three skin biopsies can lead to significant false negatives, which increases as diagnostic certainty wanes. This information is crucial for developing effective diagnostic protocols and ensures that clinicians can make informed decisions about their patients’ health.
Overview of Presentations Scheduled
CND Life Sciences will showcase their presentations throughout the AAN 2025 Annual Meeting, providing various abstracts that underscore the importance of their research. Specific details regarding these presentations include:
- Session 1: Innovations in Non-AD Dementia
- Abstract Title: A Longitudinal Quantitative Assessment of Phosphorylated Alpha-Synuclein Deposition in Dementia with Lewy Bodies
- Lead Author: Christopher Gibbons, MD, FAAN, Beth Israel Deaconess Medical Center
- Presentation Details: Program #S1007, Sunday, April 6, at 2:12 PM PT
- Abstract Title: The Syn-D Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein and Blood P-Tau 217 in Patients with Mild Cognitive Impairment
- Presentation Details: Program #S1008, Sunday, April 6, at 2:24 PM PT
- Abstract Title: An Analysis of the Number of Skin Biopsies Needed in the Detection of Phosphorylated Alpha-Synuclein
- Poster Presentation Details: Program #P9021, Tuesday, April 8, from 11:45 AM–12:45 PM PT
About CND Life Sciences
CND Life Sciences is at the forefront of developments aimed at tackling neurodegenerative diseases. Their work includes creating the Syn-One Test, which assesses phosphorylated alpha-synuclein, aiding clinicians in making accurate diagnoses for conditions such as Parkinson’s disease and DLB. The company operates a CLIA-certified and CAP-accredited laboratory, ensuring high standards in diagnostic testing and supporting neurologists throughout the country.
The Syn-One Test has already proven valuable in clinical settings, offering over 95% sensitivity in diagnosing synucleinopathies based on recent findings. With this level of accuracy, the test stands to greatly enhance diagnostic methods used by clinicians.
CND Life Sciences continues to collaborate with biopharmaceutical partners on clinical trials to promote the advancement of treatments for neurodegenerative diseases and contribute to more effective early disease detection methodologies.
Frequently Asked Questions
What is the primary focus of CND Life Sciences’ research?
The primary focus is on the detection of phosphorylated alpha-synuclein in skin biopsies to improve diagnostics for dementia with Lewy bodies and related disorders.
Who is leading the research at CND Life Sciences?
Dr. Christopher Gibbons, the Chief Scientific Officer and co-founder, is leading this significant research initiative.
Why are three biopsies recommended for accurate diagnosis?
Research indicates using fewer than three biopsies can lead to substantial false negatives, making it vital for diagnosis accuracy.
What is the Syn-One Test?
The Syn-One Test is a minimally invasive diagnostic tool designed to help clinicians accurately diagnose synucleinopathies.
When will the presentations take place?
The presentations will occur from April 5 to 9, during the American Academy of Neurology 2025 Annual Meeting in San Diego.
